Log in

NASDAQ:LNTH - Lantheus Stock Price, Forecast & News

$16.64
-0.19 (-1.13 %)
(As of 02/17/2020 04:15 AM ET)
Add
Today's Range
$16.42
Now: $16.64
$16.99
50-Day Range
$16.64
MA: $18.49
$20.51
52-Week Range
$16.42
Now: $16.64
$29.80
Volume250,116 shs
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio19.13
Dividend YieldN/A
BetaN/A
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:LNTH
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees488
Next Earnings Date2/18/2020 (Estimated)
OptionableOptionable

Receive LNTH News and Ratings via Email

Sign-up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.


Lantheus (NASDAQ:LNTH) Frequently Asked Questions

What is Lantheus' stock symbol?

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

How were Lantheus' earnings last quarter?

Lantheus Holdings Inc (NASDAQ:LNTH) released its quarterly earnings results on Thursday, October, 31st. The medical equipment provider reported $0.28 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.21 by $0.07. The medical equipment provider had revenue of $85.80 million for the quarter, compared to analysts' expectations of $83.82 million. Lantheus's revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.24 EPS. View Lantheus' Earnings History.

When is Lantheus' next earnings date?

Lantheus is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Lantheus.

What is the consensus analysts' recommendation for Lantheus?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus.

Has Lantheus been receiving favorable news coverage?

Media coverage about LNTH stock has trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Lantheus earned a news impact score of 1.8 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Lantheus.

Are investors shorting Lantheus?

Lantheus saw a increase in short interest in January. As of January 15th, there was short interest totalling 1,400,000 shares, an increase of 14.8% from the December 31st total of 1,220,000 shares. Based on an average daily volume of 360,700 shares, the short-interest ratio is presently 3.9 days. Approximately 3.7% of the shares of the stock are short sold. View Lantheus' Current Options Chain.

What other stocks do shareholders of Lantheus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include Mobileye (MBBYF), Energy Transfer LP Unit (ET), CBL & Associates Properties (CBL), Gerdau (GGB), NovaBay Pharmaceuticals (NBY), Akorn (AKRX), Cypress Semiconductor (CY), Exelixis (EXEL), Paratek Pharmaceuticals (PRTK) and AT&T (T).

Who are Lantheus' key executives?

Lantheus' management team includes the folowing people:
  • Ms. Mary Anne Heino, CEO, Pres & Director (Age 59)
  • Mr. Robert J. Marshall Jr., CFO & Treasurer (Age 52)
  • Mr. Michael P. Duffy, Sr. VP of Law & Public Policy, Gen. Counsel and Sec. (Age 58)
  • Dr. Cesare Orlandi, Chief Medical Officer (Age 69)
  • Mr. John J. Bolla, Chief Operating Officer (Age 49)

When did Lantheus IPO?

(LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

Who are Lantheus' major shareholders?

Lantheus' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (3.76%), Renaissance Technologies LLC (3.58%), Vaughan Nelson Investment Management L.P. (3.38%), LSV Asset Management (3.25%), Tamarack Advisers LP (1.66%) and Prudential Financial Inc. (1.61%). Company insiders that own Lantheus stock include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno, Timothy G Healey and Tudor Brown. View Institutional Ownership Trends for Lantheus.

Which institutional investors are selling Lantheus stock?

LNTH stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Rice Hall James & Associates LLC, Renaissance Technologies LLC, Royce & Associates LP, Citigroup Inc., Tamarack Advisers LP, AQR Capital Management LLC and Stifel Financial Corp. Company insiders that have sold Lantheus company stock in the last year include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno and Tudor Brown. View Insider Buying and Selling for Lantheus.

Which institutional investors are buying Lantheus stock?

LNTH stock was acquired by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Russell Investments Group Ltd., Bank of Montreal Can, Prudential Financial Inc., Public Sector Pension Investment Board, First Trust Advisors LP, Great West Life Assurance Co. Can and Panagora Asset Management Inc.. View Insider Buying and Selling for Lantheus.

How do I buy shares of Lantheus?

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Lantheus' stock price today?

One share of LNTH stock can currently be purchased for approximately $16.64.


MarketBeat Community Rating for Lantheus (NASDAQ LNTH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  268 (Vote Outperform)
Underperform Votes:  257 (Vote Underperform)
Total Votes:  525
MarketBeat's community ratings are surveys of what our community members think about Lantheus and other stocks. Vote "Outperform" if you believe LNTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LNTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel